Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Safiyyah Ziyad, Kristina Jordahl, Hongxiang Hu, Ethan Thompson, Susan Bal, Myo Htut, Larry Anderson, Tara Gregory, Luciano Costa, Omar Nadeem, Naomey Sarkis, Ziyan Guo, Wei-Ming Kao, Allison Kaeding, Shari Kaiser, Michael Burgess, Jesús Berdeja

Blood (2025) 146 (Supplement 1): 2223.

https://doi.org/10.1182/blood-2025-2223

Published: 2025

Journal Articles

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Sahar Ansari, Manali Kamdar, Eniko Papp, Mazyar Shadman, Jeremy Abramson, Begüm D. Topçuoglu, Pei Yang, Lara Stepan, Pradipta Ray, Amanda Przespolewski, Krishna R. Juluri, Eric Bleickardt, Debasmita Roy, Alessandro Crotta, Timothy B. Campbell, Julie A. Rytlewski, Abood Okal, Ethan Thompson, Leanne Peiser

Blood (2025) 146 (Supplement 1): 1775.

https://doi.org/10.1182/blood-2025-1775

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Pradipta Ray, Abood Okal, Miguel-Angel Perales, Sandeep Raj, Roni Shouval, Eniko Papp, Sahar Ansari, Krishna R. Juluri, Amanda Przespolewski, Debasmita Roy, Ethan Thompson, Julie A. Rytlewski, Eric Bleickardt, Alessandro Crotta, Timothy B. Campbell, Leanne Peiser

Blood (2025) 146 (Supplement 1): 3549.

https://doi.org/10.1182/blood-2025-3549

Published: 2025

Journal Articles

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

Hao Tang, Ethan Thompson, Dante Descalzi-Montoya, Jensen Wong, Sonash Nayee, Yan Li, Dhong Lee, Shari Kaiser, Debashree Basudhar

Blood (2025) 146 (Supplement 1): 95.

https://doi.org/10.1182/blood-2025-95

Published: 2025

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2023) 142 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2023-173970

Published: 2023

Journal Articles

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Eniko Papp, Sahar Ansari, Jason Wall, Ethan Thompson, Yizhe Chen, Tanya Siddiqi, William G. Wierda, Serena K. Perna, Sherilyn A. Tuazon, Abood Okal, Leanne Peiser

Blood (2023) 142 (Supplement 1): 3263.

https://doi.org/10.1182/blood-2023-180230

Published: 2023

Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser

Blood (2023) 142 (Supplement 1): 225.

https://doi.org/10.1182/blood-2023-181007

Published: 2023

Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel

Blood (2022) 140 (Supplement 1): 875–877.

https://doi.org/10.1182/blood-2022-162469

Published: 2022

Journal Articles

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Isaac W. Boss, Ethan Thompson, Allison M. Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 7116–7117.

https://doi.org/10.1182/blood-2022-163192

Published: 2022

Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel

Blood (2022) 140 (Supplement 1): 7441–7443.

https://doi.org/10.1182/blood-2022-162615

Published: 2022

Journal Articles

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

Mehmet K. Samur, Nathan Martin, Ethan Thompson, Mariateresa Fulciniti, Anil Aktas-Samur, Shari Kaiser, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 2106–2107.

https://doi.org/10.1182/blood-2022-168903

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only